Macrocyclic Factor D Inhibitors for Sustained Complement Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for medical disorders mediated by the complement system, such as autoimmune and inflammatory diseases, lack specificity and efficacy, particularly for disorders like age-related macular degeneration and rheumatoid arthritis, due to the short half-life and non-specificity of existing Factor D inhibitors.
Innovation Solution
Development of novel compounds, represented by Formulas I through IX, which act as inhibitors of the complement Factor D cascade with minimal impact on the bile salt export pump (BSEP) to treat inflammatory or immune conditions, including disorders associated with the alternative complement pathway, classical pathway, or lectin pathway, and provide prophylactic benefits against infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Factor D inhibitors are used to treat complement-mediated disorders, then complement pathway inhibition is achieved, but the compounds suffer from short half-life and lack of specificity leading to unwanted side effects
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of Factor D inhibitors to achieve optimal pharmacokinetic properties. Specifically, the macrocyclic compounds are designed with specific molecular weights, lipophilicity values, and structural features that extend half-life while maintaining complement pathway inhibition efficacy. The structural optimization includes adjusting ring size, substituent groups, and stereochemistry to improve metabolic stability and reduce clearance rates.
2Reliability
If existing Factor D inhibitors are used to treat complement-mediated disorders, then complement pathway inhibition is achieved, but the compounds lack specificity causing unwanted side effects
Solution Approach 1:
The patent applies local quality by designing macrocyclic compounds with specific local structural features that enhance binding affinity and selectivity for Factor D. The molecules incorporate specific functional groups, stereochemical configurations, and spatial arrangements that create precise molecular recognition of the Factor D active site. This localized structural optimization ensures high specificity for the target enzyme while minimizing off-target effects on other proteases or biological pathways.
3Reliability
If existing Factor D inhibitors are used, then treatment of complement-mediated disorders is provided, but the treatment lacks sustained therapeutic effect due to short half-life
Solution Approach 1:
The patent applies continuity of useful action by developing macrocyclic Factor D inhibitors with extended half-lives that maintain sustained therapeutic concentrations in the bloodstream. The compounds are designed to resist metabolic degradation through strategic placement of chemically stable bonds, incorporation of metabolically resistant structural motifs, and optimization of protein binding characteristics. This ensures continuous inhibition of the complement pathway over extended periods, reducing dosing frequency and maintaining stable therapeutic effects.
Data Source
AI summary
Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce excessive activation of complement.